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Abstract
Carbonic anhydrase IX (CAIX) is a tumor-specific protein that is upregulated during hypoxic
conditions where it is involved in maintaining the pH balance. CAIX causes extracellular
acidification, thereby limiting the uptake of weak basic chemotherapeutic agents, such as
doxorubicin, and decreasing its efficacy. The aim of this study was to determine if doxorubi-
cin efficacy can be increased when combined with the selective sulfamate CAIX inhibitor
S4. The effect of S4 on doxorubicin efficacy was tested in vitro using cell viability assays
with MDA-MB-231, FaDu, HT29 –CAIX high and HT29 –CAIX low cell lines. In addition, the
efficacy of this combination therapy was investigated in tumor xenografts of the same cell
lines. The addition of S4 in vitro increased the efficacy of doxorubicin in the MDA-MB-231
during hypoxic exposure (IC50 is 0.25 versus 0.14 μM, p = 0.0003). Similar results were
observed for HT29—CAIX high with S4 during normoxia (IC50 is 0.20 versus 0.08 μM,
p<0.0001) and in the HT29 –CAIX low cells (IC50 is 0.09 μM, p<0.0001). In vivo doxorubicin
treatment was only effective in the MDA-MB-231 xenografts, but the efficacy of doxorubicin
was decreased when combined with S4. In conclusion, the efficacy of doxorubicin treatment
can be increased when combined with the selective sulfamate CAIX inhibitor S4 in vitro in
certain cell lines. Nevertheless, in xenografts S4 did not enhance doxorubicin efficacy in the
FaDu and HT29 tumor models and decreased doxorubicin efficacy in the MDA-MB-231
tumor model. These results stress the importance of better understanding the role of CAIX
inhibitors in intratumoral pH regulation before combining them with standard treatment
modalities, such as doxorubicin.
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Introduction
The immature and inadequate vasculature of solid tumors prevents oxygen and nutrients
supply to certain areas in those tumors. This hypoxic microenvironment selects for a more
aggressive tumor phenotype and promotes invasion, migration, and thereby metastases for-
mation [1, 2]. These hypoxic tumor cells are known to be more resistant to standard treat-
ment modalities (e.g. radio- and chemotherapy), highlighting the importance of developing
new, or increasing the efficacy of already available, therapies to specifically target hypoxic
tumor cells [2–5].
To meet with the high energy demand, tumor cells switch their energy metabolism to glycol-
ysis in hypoxic but also in well-oxygenated areas in the tumors, i.e. the Warburg effect. The
increase in glycolytic energy production leads to the production of high concentrations of acids
(e.g. lactate and carbon dioxide) [6]. To aid in maintaining cellular pH homeostasis, carbonic
anhydrase IX (CAIX) expression becomes transcriptionally upregulated through stabilization
of hypoxia-inducible factor 1 (HIF1-α), although alternative hypoxia responses also play a role
[7]. CAIX catalyzes the conversion of water and the cellular produced carbon dioxide to bicar-
bonate and protons. The protons contribute to the hostile acidic extracellular environment,
whereas the bicarbonate is transported back intracellularly to aid in maintaining a slightly alka-
line pH [8, 9]. The important role that CAIX plays in maintaining the cellular pH balance com-
bined with its predominant expression on hypoxic tumor cells make it an attractive target for
treatment [2, 4, 5, 10]. The importance of CAIX on tumors is strengthened further by the sig-
nificant association between high tumoral CAIX expression and a worse prognosis in patients
with many different cancer types [11]. CAIX expression might therefore also be a valuable
imaging tool for future clinical practice [12–14]. Previously, several CAIX inhibitors have been
shown to be effective in reducing primary tumor growth in vivo, either as a single treatment or
in combination with radiotherapy [15–17].
CAIX inhibition is also able to increase the efficacy of certain chemotherapeutics, such as
the anthracycline antitumor antibiotic doxorubicin [18, 19]. This chemotherapeutic agent is
commonly used in combination treatment regimens in different cancer types, of which breast
cancer is a prime example [20]. Doxorubicin diffuses passively across the cell membrane, inter-
calates the DNA and induces cell death. However, since doxorubicin is a weak basic compound
the reduced extracellular pH in hypoxic areas of tumors prevents passive drug uptake, referred
to as the ion trapping model. This model predicts pH modulating therapies are capable of
increasing the uptake and efficacy of doxorubicin [21–23]. Inhibiting CAIX function reduces
the degree of extracellular acidification [9, 15, 16, 19, 24], which may thereby increase the
uptake and efficacy of doxorubicin. In line with the ion trapping model non-specific carbonic
anhydrase inhibition with acetazolamide has been shown previously to increase doxorubicin
uptake in vitro [18], although the carbonic anhydrase isoform responsible for this effect
remained elusive, but was suggested to be CAIX. Furthermore, evidence exist that CAIX inhibi-
tion is able to increase doxorubicin efficacy in vivo [19].
The ureido-substituted sulfamate S4 is a member of an alternative class of CAIX inhibitory
molecules that were synthesized with high selectivity for CAIX [25] and exhibited significant
anti-proliferative efficacy in vitro in different breast cancer tumor models [26, 27]. Although
S4 was ineffective in reducing primary tumor growth in vivo, the compound decreased spon-
taneous lung metastases formation in an orthotopic MDA-MB-231 breast cancer model [25].
This study aims to determine for the first time whether the specific inhibition of CAIX with
the sulfamate S4 is able to increase doxorubicin efficacy, both in vitro and in vivo, and deter-
mine if specific CAIX targeting or CAIX knockdown will be able to increase doxorubicin
efficacy.
Combination CAIX Inhibitor S4 with Doxorubicin
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Methods
Cell culture
MDA-MB-231 triple negative breast adenocarcinoma (HTB-26), FaDu pharynx squamous cell
carcinoma (HTB-43), and HT29 colorectal adenocarcinoma (HTB-38) tumor cells, all obtained
from ATCC, were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Lonza) supple-
mented with 10% Fetal Bovine Serum (FBS, Lonza). Cells were maintained in humidified incu-
bators with 5% carbon dioxide in which they were allowed to attach overnight before the start
of experiments.
Transfection
Inducible genetic CA9 knockdown (KD) cells were constructed using the pTRIPZ doxycy-
cline inducible system (Open Biosystems). Specific shRNA targeting CA9, based on Sigma
TRCN0000180210, was inserted in the EcoR1 –Xho1 site of the vector. Lentivirus was made
in HEK293FT cells (Thermo Fisher Scientific, # R700-07) and used to infect HT29 cells.
These HT29 cells were exposed to low concentrations of doxycycline (1 μg/ml, Sigma-
Aldrich) one week prior to the start of experiments to induce a sufficient CAIX KD, as CAIX
half-life is approximately 38 hours [28]. HT29 cells exposed to doxycycline, i.e. with a CAIX
KD, are defined as HT29 –CAIX low cells, whereas HT29 cells not exposed to doxycycline,
i.e. with normal CAIX levels, are defined as HT29 –CAIX high cells.
Immunoblotting
Adherent cells were exposed to hypoxic conditions for 24 hours in a hypoxic chamber (MACS
VA500 microaerophilic workstation, DonWhitley Scientific, UK). The atmosphere in the
chamber consisted of 0.2% O2, 5% CO2 and residual N2. Normoxic dishes were incubated in
parallel in ambient air with 5% CO2. Protein isolates were prepared by scraping cells in RIPA,
sonicating the samples, and centrifugation them to remove cellular debris. Protein concentra-
tions were measured using Bradford protein quantification reagent (Bio-rad). Western Blot
was performed using primary antibodies against CAIX (M75, kindly provided by Professor Sil-
via Pastorekova, Institute of Virology, Slovak Academy of Science, Slovak Republic), and beta-
actin (MP Biomedicals, #691001) as a reference protein. Primary antibodies were incubated
overnight at 4°C, whereas HRP (horseradish peroxidase)-linked secondary antibody (Cell Sig-
nalling, #7076) was incubated for 1 hr at room temperature (RT).
qPCR
Cells were exposed to 0.2% O2 for 24 hours after which RNA was isolated using the NucleoS-
pin1 RNA kit (Macherey Nagel). Thereafter cDNA was synthesized using iScript mix (Bio-
Rad) and gene expression of CAIX (F-CATCCTAGCCCTGGTTTTTGG, R-GCTCACACCCC
CTTTGGTT) and vascular endothelial growth factor (VEGF) (F- GACTCCGGCGGAAGCAT,
R- TCCGGGCTCGGTGATTTA) was determined using power SYBR1 Green I (Applied Biosys-
tems). Expression of 18S RNA (F- AGTCCCTGCCCTTTGTACACA, R- GATCCGAGGGCCT
CACTAAAC) levels was used as a reference.
Cell viability assays
Tumor cells were seeded with 6000, 1000, or 4000 cells per well for MDA-MB-231, FaDu, or
HT29, respectively, in flat bottom 96-well plates. The next day cells were exposed to hypoxia
(0.2% O2) and medium was replaced by low serum medium (0.2% FBS) containing vehicle
(DMSO, final concentration 0.75%), or the sulfamate CAIX inhibitor S4 (33 μM, kindly
Combination CAIX Inhibitor S4 with Doxorubicin
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provided by Professor Claudiu Supuran, University of Florence, Italy). It has previously been
demonstrated that 33 μM of S4 was effective in reducing cell viability [25–27]. Simultaneously,
cells were exposed to different concentrations of doxorubicin (ranging from 0.01 to 5 μM,
Sigma-Aldrich). After 24 hours medium with compounds was replaced with normal DMEM
with 10% FBS. Cells were allowed to grow for an additional 72 hrs under normoxic conditions
and cell viability was measured thereafter using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide (MTT, Sigma-Aldrich) for FaDu, or Alamar Blue (Life Technology) in
MDA-MB-231 and HT29 cells. Half the HT29 were exposed to doxycycline (1 μg/ml) one
week prior to the experiment and for the entire duration of the experiment to test both HT29 –
CAIX high and HT29 –CAIX low cells. Treatment response was quantified in terms of IC50,
i.e. the concentration of a drug that gives half-maximal response
In vivo experiments
All animal experiments were ethically approved by the ethical committee on animal experi-
mentation of the university of Manchester (PPL 70/7760) and the university of Maastricht
(DEC 2008–025) and performed in accordance to local legislation and guidelines. Eight weeks
old NMRI nu/nu mice (Charles River) were subcutaneously injected with MDA-MB-231,
FaDu, or HT29 tumor cells resuspended in Matrigel (Corning). Half of the mice implanted
with the HT29 cells were provided with water containing doxycycline (2 g/l) and sucrose (5%)
ad libitum during the entire experiment to obtain HT29 –CAIX high and HT29 –CAIX low
tumor xenografts. For each treatment group 6–8 animals were used. Tumors were measured
three times a week in three orthogonal dimensions to calculate tumor volume based on the for-
mula of an ellipsoid. Treatment started when tumors reached a volume of 100–150 mm3. A
treatment cycle consisted of a ‘five days on, two days off’ schedule with either vehicle (4%
DMSO in saline) or S4 (10 mg/kg ip for MDA-MB-231 and FaDu, and 25 mg/kg ip for HT29).
Doxorubicin or vehicle control (PBS) was administered ip once a week (5 mg/kg on day 4 of
treatment cycle). Total body weight was measured repeatedly for the duration of the study to
monitor possible treatment-induced toxicity. In the experiment with the HT29 –CAIX high
and HT29 –CAIX low models a parallel group of mice was sacrificed directly after the first
treatment cycle, i.e. after the last S4 injection, to investigate levels of CAIX expression in the
tumors. Treatment response was quantified as time to reach 2, 5 or 7 times start volume
(T2xSV, T5xSV, and T7xSV, respectively) depending on the growth of the tumor model.
Immunohistochemical staining
Frozen 7 μm tumor sections were fixed in acetone (4°C, 10 min), air-dried and rehydrated in
PBS. The sections were incubated with a mixture of polyclonal rabbit anti-CAIX (Novus Bio-
logicals NB100-417) and FITC-conjugated IgG1 mouse monoclonal anti-pimonidazole (clone
4.3.11.3, Hypoxyprobe™-1 Plus Kit) antibodies overnight at 4°C, followed by incubation with
secondary goat anti-rabbit AlexaFluor 594 (Invitrogen) antibody for 1 hr at RT. Images were
acquired as described previously in detail [29].
Statistical analysis
All statistical analyses were performed using GraphPad Prism (version 5.03). Curve fits of cell
viability assays were compared with the extra sum-of–squares F test. Average tumor growth
curves were fitted with linear regression. Differences in means between groups were compared
with unpaired t-tests. P<0.05 indicates statistical significant difference.
Combination CAIX Inhibitor S4 with Doxorubicin
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Results
For both MDA-MB-231 and FaDu cell lines an increased CAIX expression upon hypoxic expo-
sure was observed (Fig 1A and 1B). Cell viability of MDA-MB-231 cells decreased with increas-
ing concentrations of doxorubicin under both normoxic and hypoxic conditions but this effect
was slightly more pronounced during normoxia: IC50 0.13 vs. 0.25 μM, p = 0.0025 (Fig 1C).
While S4 did not increase the sensitivity of MDA-MB-231 cells during normoxia, IC50 reduced
to 0.14 μM during hypoxia (p = 0.0003), suggesting that S4 mediated CAIX inhibition increases
doxorubicin efficacy during hypoxia exposure in MDA-MB-231 cells. In contrast, viability of
FaDu cells decreased with increasing doxorubicin concentration independent of oxygen con-
centrations and this effect could not be enhanced by S4 under hypoxia (Fig 1D).
To test if the efficacy of S4 is dependent on CAIX expression, HT29 cells with a doxycy-
cline-inducible knockdown (KD) of CA9 were generated. HT29 cells were chosen since these
cells are shown to be sensitive to CAIX inhibition [15, 16]. Exposing these HT29 cells to doxy-
cycline (1 μg/ml) for one week significantly reduced the mRNA levels of CAIX, but not of a dif-
ferent HIF1-α target, i.e. VEGF, thereby indicating the change in CAIX mRNA levels to be
independent on changes in HIF1-α (Fig 2A). Similar results were obtained for protein expres-
sion of CAIX which was decreased by doxycycline exposure of HT29 cells both in normoxia
and hypoxia (Fig 2B and 2C). Without doxycycline CAIX expression of HT29 cells was how-
ever similar to the parental HT29 cells (Fig 2B and 2C). These HT29 cells are therefore defined
as HT29 –CAIX high, when not exposed to doxycycline, and HT29 –CAIX low, when a doxy-
cycline-induced CAIX knockdown is present.
Contrary to what was expected, HT29 –CAIX high cells were more sensitive to doxorubicin
under hypoxic as compared to normoxic conditions (IC50 0.10 vs 0.20 μM, p = 0.0013) (Fig
2D). Doxorubicin efficacy however did increase when cells were exposed to S4 during nor-
moxic conditions (IC50 0.20 vs 0.08 μM, p<0.0001, Fig 2D), but decreased slightly during hyp-
oxia (IC50 is 0.10 vs 0.18 μM, p = 0.0039, Fig 2D). Sensitivity to doxorubicin under normoxic
conditions was increased for HT29 –CAIX low as compared to HT29 –CAIX high cells (IC50
0.09 vs 0.20 μM, p<0.0001, Fig 2D and 2E), suggestive of a CAIX dependent mechanism of
increased doxorubicin efficacy. The decreased CAIX expression in HT29 –CAIX low cells
might also explain the lack of effect of S4 on doxorubicin sensitivity in these cells during nor-
moxic conditions (IC50 0.09 vs 0.10 μM, p = 0.0972, Fig 2E), or the similar sensitivity during
hypoxia (IC50 0.09 vs 0.08 μM, p = 0.6465, Fig 2E). In contrast however, doxorubicin sensitiv-
ity decreased when HT29 –CAIX low cells were exposed to S4 during hypoxic conditions
(IC50 0.08 vs 0.17 μM, p = 0.0002, Fig 2E). Higher serum concentrations abrogated the effect
of S4 on doxorubicin efficacy (S1 Fig), which may be because of the high binding affinity of S4
to bovine serum albumin (data not shown).
To further study and validate the in vitro findings, the combination treatment of S4 with
doxorubicin was tested in tumor-bearing mice. No acute toxicity in these animals was observed
up to three treatment cycles, as no significant changes in total body weight were observed (S2
Fig). Doxorubicin treatment significantly inhibited MDA-MB-231 tumor growth as compared
to vehicle (Fig 3A): time to reach 5 times starting volume (T5xSV) were 14.3 and 8.2 days,
respectively (p<0.01, Fig 3B). Contradictory to the in vitro data and our hypothesis, S4 treat-
ment abrogated the effect of doxorubicin (p<0.01) in MDA-MB-231. In FaDu xenografts
doxorubicin treatment either alone or in combination with S4 was ineffective in reducing
tumor growth as compared to vehicle treated mice (T7xSV 10.8, 12.6 and 11.8 days, respec-
tively, Fig 3C and 3D).
To test whether the efficacy of combined treatment of doxorubicin with S4 in vivo depends
on CAIX expression we employed the HT29 –CAIX high and HT29 –CAIX low tumor models.
Combination CAIX Inhibitor S4 with Doxorubicin
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The HT29 –CAIX low tumor model exhibited a markedly reduced expression of CAIX by
doxycycline exposure in the drinking water, although residual CAIX expression could still be
observed. In both the HT29 –CAIX high and HT29 –CAIX low tumor models pimonidazole-
positive labeling demonstrated presence of hypoxia (S3 Fig). Single S4 or doxorubicin treat-
ment did not inhibit the growth of HT29 –CAIX high (Fig 4A) or HT29 –CAIX low (Fig 4B)
tumors. Tumor response to doxorubicin treatment was not improved by knockdown of CAIX
as time to reach 2 times start volume (T2XSV) was not statistically different (19.4 vs 25.7 days,
p = 0.5144, Fig 4C and 4D). In addition, combination of S4 with doxorubicin was unable to
increase doxorubicin efficacy in HT29 –CAIX high (T2XSV 19.4 vs 22.4, p = 0.5801, Fig 4C),
or in HT29 –CAIX low tumors (T2XSV 25.7 vs 15.8, p = 0.3274, Fig 4D). Additional treatment
cycles were also ineffective in exerting an effect on tumor growth and caused severe toxicity in
animals.
Discussion
In the present study we investigated whether doxorubicin treatment efficacy can be enhanced
when combined with the CAIX specific sulfamate inhibitor S4 [25–27, 30]. Previously, CAIX
inhibition has been shown to potentiate the efficacy of standard treatment modalities, such as
radio- and chemotherapy [15, 16, 19]. Furthermore, non-isoform specific CA inhibition with
acetazolamide can increase doxorubicin uptake, thereby making it more effective [18]. The ion
trapping model explains the higher efficacy of the weak basic anthracycline antitumor antibi-
otic doxorubicin due to an increased uptake when the balance between intracellular and extra-
cellular pH is shifted towards a reduced extracellular acidification upon hypoxia when treated
with selective CAIX inhibitors [21–23]. The results of this study demonstrate that the selective
Fig 1. Effect of S4 on doxorubicin sensitivity in MDA-MB-231 and FaDu cells.CAIX protein expression is higher during hypoxia in
MDA-MB-231 and FaDu cells (A). Quantification of three independent biological repeats shows an almost twofold increase in CAIX
expression (normalized to actin expression levels) in both cell lines (B). Cell viability assays of MDA-MB-231 (C) and FaDu cells (D) with
increasing concentrations of doxorubicin. Cells were exposed to vehicle (black) or S4 (green) during normoxia (N), or to vehicle (red) or S4
(blue) during hypoxia (H). Results of three independent biological repeats are shown (mean ± SEM).
doi:10.1371/journal.pone.0161040.g001
Combination CAIX Inhibitor S4 with Doxorubicin
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CAIX inhibitor S4 increased doxorubicin efficacy in vitro in MDA-MB-231 cells, specifically
in hypoxic conditions. These results could however not be found in FaDu, HT29 –CAIX low
and HT29 –CAIX high cells; although for the latter an increased efficacy of doxorubicin was
observed during normoxia when combined with S4. This increase in doxorubicin efficacy
therefore appeared to depend on the levels of CAIX expression in normoxic HT29 cells. Doxo-
rubicin efficacy however was not modulated by S4 under hypoxic conditions, which are essen-
tial for full CAIX activation [24, 31]. Nevertheless, this could be due to an incomplete CAIX
inhibition that would still reduce the extracellular pH and thereby reduce doxorubicin uptake
and efficacy.
To validate the efficacy of S4 treatment in vivo experiments were conducted using the same
cell lines, since tumor hypoxic and acidic microenvironment might be an important factor
influencing the potential of S4 to enhance doxorubicin cytotoxicity. Similar to the previous
report [25] S4 monotherapy did not inhibit the growth of any of the tumor models included in
this study. These results are in line with histological evaluation of tumor microenvironmental
Fig 2. Effect of S4 on doxorubicin efficacy in HT29 –CAIX high and HT29 –CAIX low cells. Exposing HT29 cells to doxycycline (doxy) reduced
CA9mRNA levels during normoxia (N) and hypoxia (H), whereas VEGF levels were unaffected (A). CAIX protein levels minimized in HT29 –CAIX
low cells when exposed to doxycycline (B). Quantification of three independent biological repeats showed minimal residual CAIX protein expression
in HT29 –CAIX low cells as compared to parental cells or HT29 –CAIX high cells without a KD (C). Cell viability assays of HT29 –CAIX high (D) or
HT29 –CAIX low cells (E) with increasing concentrations of doxorubicin. Cells were exposed to vehicle (black) or S4 (green) during normoxia (N), or
to vehicle (red) or S4 (blue) during hypoxia (H). Results of three independent biological repeats are shown (mean ± SEM).
doi:10.1371/journal.pone.0161040.g002
Combination CAIX Inhibitor S4 with Doxorubicin
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characteristics in SCCNij202 xenografts demonstrating that S4 treatment did not have an effect
on proliferation, apoptosis, necrosis, and hypoxia [32]. Taken together the data indicate that S4
lacks anti-cancer efficacy in vivo in primary tumors. Previously S4 has been described to reduce
migration of MDA-MB-231 tumor cells, and prevent invasion of ex vivo breast cancer spher-
oids [25, 27]. Furthermore, treatment of orthotopic MDA-MB-231 xenografts with S4 reduced
the number of spontaneous lung metastases [25]. In addition, it has been shown that S4 can
increase ectodomain shedding of CAIX, both in vitro and in vivo, although the exact relevance
and mechanism of this finding requires additional studies [30, 32].
In this study doxorubicin treatment was only effective in reducing tumor growth in the
MDA-MB-231 xenografts, whereas no effect was observed in the FaDu, HT29 –CAIX high and
HT29 –CAIX low tumor models. This difference between models is unlikely caused by any
intrinsic variation in doxorubicin sensitivity, as no differences were observed in vitro or in pre-
vious reports [33]. The tumor microenvironment might therefore be responsible for this differ-
ence in doxorubicin response. Quantification of the exogenous hypoxia marker pimonidazole
in FaDu xenografts revealed the average hypoxic fraction to range between 10–20% [34–36].
The hypoxic fraction of the subcutaneous HT29 –CAIX high tumors was also approximately
10% and increased to 20% in the HT29 –CAIX low tumors in previous experiments (data not
shown). In contrast however, orthotopic MDA-MB-231 xenografts implanted in the mammary
fat pad have a hypoxic fraction of only 5% [37], whereas the hypoxic fraction is estimated to be
Fig 3. Effect of S4, doxorubicin, or the combination of both, on MDA-MB-231 and FaDu tumor xenograft growth.
Relative tumor volume (mean ± SEM) of MDA-MB-231 (A) and FaDu (C) xenografts treated with vehicle (black), S4
(green), vehicle with doxorubicin (red), or S4 with doxorubicin (blue). Linear fits from relative tumor growth were used to
estimate the mean time to reach 5 times start volume (T5XSV) of MDA-MB-231 (B) or 7 times start volume (T7XSV) of
FaDu (D) xenografts. ** indicates statistical significance with p<0.01.
doi:10.1371/journal.pone.0161040.g003
Combination CAIX Inhibitor S4 with Doxorubicin
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approximately 7% for subcutaneous tumors (data not shown). Hypoxic areas in tumors are
characterized by extracellular acidification, which would reduce doxorubicin uptake and
thereby decrease its efficacy. The relatively lower amount of hypoxia in MDA-MB-231 tumors
as compared to FaDu and HT29 tumors could therefore explain the reduced efficacy of doxo-
rubicin in the latter tumor model. Furthermore, the difference in doxorubicin efficacy between
HT29 and MDA-MB-231 tumors can likewise be explained by a relatively higher activity of
CAIX in HT29 cells as compared to the MDA-MB-231 cells [18], leading to a higher degree of
extracellular acidification and as a result reduced doxorubicin efficacy. This is further sup-
ported by the results obtained in spheroid models showing that MDA-MB-231 cells are more
sensitive to doxorubicin as compared to HT29 cells [38].
Treating HT29 tumor-bearing mice with doxorubicin was reported previously to be effec-
tive [19]. The lack of effect observed in this study might partly be explained by retention of
doxorubicin in the abdominal cavity after intraperitoneal injections [39], as opposed to intrave-
nous injections used previously [19]. This alternative administration route might therefore pre-
vent adequate distribution of doxorubicin to xenograft tumors with poorer vasculature and
higher hypoxic fraction, i.e. FaDu and HT29. We were unable to increase the doses of doxoru-
bicin in this study due to severe cardiac toxicity caused by doxorubicin after multiple treatment
cycles [40].
Fig 4. Effect of S4, doxorubicin, or the combination of both, on HT29 –CAIX high and HT29 –CAIX low tumor xenograft
growth.Relative tumor volume (mean ± SEM) of HT29 –CAIX high (A) or HT29 –CAIX low xenografts (B) treated with vehicle
(black), S4 (green), vehicle with doxorubicin (red), or S4 with doxorubicin (blue). Linear fits from relative tumor growth were
used to estimate the mean time to reach 2 times start volume (T2XSV) of HT29 –CAIX high (C) or HT29 –CAIX low (D)
xenografts.
doi:10.1371/journal.pone.0161040.g004
Combination CAIX Inhibitor S4 with Doxorubicin
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In conclusion, treatment with the sulfamate CAIX inhibitor S4 has no monotherapeutic effect
and is unable to increase doxorubicin efficacy. In contrast, S4 abrogated the effect of doxorubicin
in MDA-MB-231 tumors. The mechanism underlying this reduction in doxorubicin efficacy
remains unclear. Nevertheless, these results, in combination with the pharmacokinetic character-
istics of S4 after oral and intravenous administration (S4 Fig) suggest sufficient concentrations of
S4 might have reached the tumor. Previously a different class of CAIX inhibitor has been shown
to increase doxorubicin efficacy and also exert an effect as single agent therapy [19]. These con-
tradictory findings stress the importance of further investigations to better understand the mech-
anism of action of different classes of CAIX inhibitors before being implemented as anti-cancer
agents in combination with standard treatment modalities such as doxorubicin treatment.
Supporting Information
S1 Fig. Cell viability assay of the HT29 –CAIX high and HT29 –CAIX low cells with 10%
FBS. Cell viability assays of HT29 –CAIX high (A) or HT29 –CAIX low cells (B) with increas-
ing concentrations of doxorubicin. Cells were exposed to vehicle (black) or S4 (green) during
normoxia (N), or to vehicle (red) or S4 (blue) during hypoxia (H). Results of three independent
biological repeats are shown (mean ± SEM).
(TIF)
S2 Fig. Relative total body weight of mice with different tumor xenografts.Mice were
implanted with MDA-MB-231 (A), FaDu (B), or HT29 –CAIX high (C) or HT29 –CAIX low
(D) xenografts. Relative total body weight (mean ± SEM) of mice treated with vehicle (black),
S4 (green), vehicle with doxorubicin (red), or S4 with doxorubicin (blue) showed no signs of
acute toxicity in any of the treatment groups for any of the included tumor models.
(TIF)
S3 Fig. Validation CAIX expression in HT29 –CAIX high and HT29 –CAIX low xeno-
grafts. CAIX expression (red) and pimonidazole-labelled hypoxia (green) in the HT29 –CAIX
high tumors, and the HT29 –CAIX low xenografts by addition of doxycycline in the drinking
water of the mice.
(TIF)
S4 Fig. Pharmacokinetic studies with S4. A single dose of S4 was administered either intrave-
nously (5 mg/kg) (A) or orally (50 mg/kg) (B) in male CD1 mice. S4 was dissolved in 12.5%
ethanol, 37.5% triethylene glycol, and 50% saline. Blood samples were taken at 7 different time
points (n = 3 mice per time point) after injection and plasma was isolated. Plasma was mixed
with methanol, centrifuged and the supernatant was transferred to mass spectrometry plate for
LC-MS/MS analysis. From the single intravenous administration several parameters could be
estimated (C). From the oral administration these parameters could not be estimated because
the concentration curve over time was too inaccurate. The curve after oral injection however
does suggest S4 to be slowly resorbed out of the intestine. Intraperitoneal injection of S4 might
therefore form a depot at the injection site, thereby only releasing limited concentrations in the
blood and eventually reaching the tumor. S4 might thereby only exert an effect in certain sensi-
tive tumor models. These studies were performed by Cyprotex Ltd. (Macclesfield, UK) as a
part of the EU 7th framework programMETOXIA (ref. 2008–222741) funded initiative.
(TIF)
S1 File. Raw data from cell viability assays doxorubicin with or without S4. The data of all
three independent biological repeats is included of all cell lines described in the manuscript.
(XLSX)
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S2 File. Raw data of CAIX and VEGF gene expression of the inducible genetic CA9 knock-
down HT29 cells.Q-PCR data of three independent repeats is included of HT29 –CAIX high
and HT29 –CAIX low cells exposed to normoxic and hypoxic conditions.
(XLSX)
S3 File. Measured tumor volume and total body weight of MDA-MB231 tumor-bearing
mice. Tumor volumes were normalized to start of treatment and tumor growth was fitted with
linear regression fits to extrapolate the time to reach 5 times start volume (T5xSV). Group 1 was
treated with vehicle, group 2 was treated with S4, group 3 was treated with doxorubicin in com-
bination with vehicle, and group 4 was treated with the combination of doxorubicin with S4.
(XLS)
S4 File. Measured tumor volume and total body weight of FaDu tumor-bearing mice.
Tumor volumes were normalized to start of treatment and tumor growth was fitted with linear
regression fits to extrapolate the time to reach 7 times start volume (T7xSV). Group 1 was
treated with vehicle, group 2 was treated with S4, group 3 was treated with doxorubicin in com-
bination with vehicle, and group 4 was treated with the combination of doxorubicin with S4.
(XLS)
S5 File. Measured tumor volume and total body weight of HT29 –CAIX high and HT29 –
CAIX low tumor-bearing mice. Tumor volumes were normalized to start of treatment and
tumor growth was fitted with linear regression fits to extrapolate time to reach 2 times start vol-
ume (T2xSV). Doxycycline (Doxy) was administered in the drinking water to induce a CAIX
knockdown. Doxorubicin is abbreviated as Doxo, where +/- indicates compound or vehicle
treatment, respectively.
(XLSX)
S6 File. Raw data of pharmacokinetic analyses of S4 administration. Concentration of S4
were measured at the indicated time points (n = 3 mice per time point) after both intravenous
and oral administration of S4.
(XLSX)
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